Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia

Highlights • Cross-resistance is observed between BEN, CLB and FLU in CLL cells. • Some BEN-resistant cells may respond to dADO/PEN. • CLL cells with a del 17p display resistance to BEN, CLB and FLU. • BEN induces apoptosis through the mitochondrial and death receptor pathways. • Equivalent synergis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2016-11, Vol.50, p.63-71
Hauptverfasser:	Kost, Sara E.F, Bouchard, Eric D.J, LaBossière, Élise, Ye, Xibiao, Queau, Michelle L, Liang, William S, Banerji, Versha, Gibson, Spencer B, Katyal, Sachin, Johnston, James B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Deaminase Inhibitors Antineoplastic Agents, Alkylating - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis - drug effects Bendamustine Bendamustine Hydrochloride - therapeutic use Chemoresistance Chlorambucil - therapeutic use Chronic lymphocytic leukemia Deoxyadenosines - therapeutic use DNA Breaks, Double-Stranded - drug effects Drug Synergism Drug synergy Hematology, Oncology and Palliative Medicine Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - pathology Nucleoside analogs Pentostatin Pentostatin - therapeutic use Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!